aTyr Pharma, Inc. (NASDAQ:LIFE) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

A number of other research firms have also issued reports on LIFE. BMO Capital Markets reaffirmed a “hold” rating on shares of aTyr Pharma in a research report on Wednesday, May 24th. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Piper Jaffray Companies began coverage on aTyr Pharma in a report on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $4.27.

Shares of aTyr Pharma (NASDAQ:LIFE) traded up 12.12% during trading on Friday, hitting $3.70. The stock had a trading volume of 219,556 shares. The company’s 50 day moving average price is $3.15 and its 200 day moving average price is $3.42. The stock’s market cap is $88.20 million. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.06. Equities research analysts expect that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “aTyr Pharma, Inc. (LIFE) Upgraded to “Sell” by ValuEngine” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at

In other news, Director Paul Schimmel purchased 94,336 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were purchased at an average price of $2.65 per share, for a total transaction of $249,990.40. Following the purchase, the director now directly owns 40,440 shares of the company’s stock, valued at approximately $107,166. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Mendlein purchased 37,736 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were purchased at an average price of $2.65 per share, for a total transaction of $100,000.40. The disclosure for this purchase can be found here. Corporate insiders own 33.30% of the company’s stock.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC increased its position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 38,800 shares of the biotechnology company’s stock after buying an additional 700 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of aTyr Pharma worth $136,000 as of its most recent SEC filing. 46.66% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with's FREE daily email newsletter.